Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | TSHR | P16473 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptolamide SCHEMBL1814750 | 1.00 | ADORA3 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Glycyclamide SCHEMBL49386 | 1.00 | ADORA3 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Glycyclamide SCHEMBL21722119 | 0.99 | ADORA3 (0.97) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Tolpentamide SCHEMBL2109411 | 0.98 | ADORA3 (0.97) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL5931113 | 0.87 | ADORA3 (0.77) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Acetohexamide SCHEMBL15669221 | 0.86 | ALDH1A1 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Acetohexamide SCHEMBL37620 | 0.86 | ALDH1A1 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL24162711 | 0.85 | PPARG (0.76) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL23007557 | 0.85 | ADORA3 (0.74) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL23736042 | 0.85 | ADORA3 (0.74) | ADORA3ALDH1A1TSHRLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966993-B2 | Pharmaceutical composition comprising a sulfonylurea drug and preparation method thereof | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | claimed |
| EP-3556371-A1 | PHARMACEUTICAL COMPOSITION OF SULFONYLUREA DRUGS AND PREPARATION METHOD THEREFOR | Jiangsu Aosaikang Pharmaceutical Co., Ltd (CN) | 2019-10-23 | — | — | EP | claimed |
| CN-108210501-B | A kind of medicinal composition for injections of sulfonylureas and preparation method thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2019-03-08 | — | — | CN | claimed |
| CN-108210501-A | A kind of medicinal composition for injections of sulfonylureas and preparation method thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2018-06-29 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-101897697-A | Sugar-lowering drug composition and application | BEIJING AOSA PHARMED RES CT CO LTD | 2010-12-01 | — | — | CN | claimed |
| CN-101897696-A | Sugar-lowering drug composition and application thereof | BEIJING AOSA PHARMED RES CT CO LTD | 2010-12-01 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101008631-B | Reagent kit for predicting therapeutic effect of sulfonylurea drugs | BEIJNG HAFO BIOMEDICAL RES CT INC | 2010-05-12 | — | — | CN | claimed |
| CN-101695492-A | Pharmaceutical composition containing statin-type lipid-lowering medicaments, sulphonylurea-type hypoglycemic medicaments and nicotinic acid | BEIJING AOSA PHARMED CO LTD | 2010-04-21 | — | — | CN | claimed |
| CN-101445824-A | Primer for detecting sulfonylureas receptor 1 gene polymorphism sites, the application thereof and kits thereof | BEIJING HUAANFO MEDICINE RES C (CN) | 2009-06-03 | — | — | CN | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| CN-101103993-A | Hypoglycemic medicine composition | BEIJING HUAANFO MEDICINE RES C (CN) | 2008-01-16 | — | — | CN | claimed |
| CN-101008631-A | Reagent kit for predicting therapeutic effect of sulfonylurea drugs | BEIJNG HAFO BIOMEDICAL RES CT (CN) | 2007-08-01 | — | — | CN | claimed |
| CN-101008032-A | Uses and method for polymorphic point genetype for predicting sulfaurea drugs effect | BEIJING HUA ANFO MEDICINE RES (CN) | 2007-08-01 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1895674-A | Medicinal composition containing sulfourea antidiabetic medicine and vitamine B | HUAANFU PHARMACEUTICAL RES CT (CN) | 2007-01-17 | — | — | CN | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| CN-1252273-A | Preparation and application of seleno-methionine chrome yellow urea as hypoglycemic | DONG GUOCHEN (CN) | 2000-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966993-B2 | Pharmaceutical composition comprising a sulfonylurea drug and preparation method thereof | IAPP, GCG, SLC5A1 | ADORA3 761/4885ALDH1A1 2329/4885TSHR 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.